Evidence map›Paper›PMID 38315779›Full record

ArticleCancer research2024

Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development.

Lior Goldberg, Eric R Haas, Ryan Urak, Vibhuti Vyas, Khyatiben V Pathak, Krystine Garcia-Mansfield, Patrick Pirrotte, Jyotsana Singhal, James L Figarola, Ibrahim Aldoss and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Lior GoldbergDepartment of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0002-1643-7616
Eric R HaasDepartment of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0003-2962-9331
Ryan UrakDepartment of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-5289-5000
Vibhuti VyasDepartment of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-6771-5666
Khyatiben V PathakIntegrated Mass Spectrometry Shared Resource, City of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0000-0002-8050-0747
Krystine Garcia-MansfieldIntegrated Mass Spectrometry Shared Resource, City of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0000-0002-9089-2254
Patrick PirrotteIntegrated Mass Spectrometry Shared Resource, City of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0000-0003-1360-6039
Jyotsana SinghalDivision of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0009-0004-0119-9370
James L FigarolaDivision of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0003-3948-6282
Ibrahim AldossDepartment of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-9564-4498
Stephen J Forman *Department of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0002-2803-4152
Xiuli Wang *Department of Hematology and Hematopoietic Cell Transplantation, T-cell Therapeutics Research Laboratories, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.ORCID 0000-0001-5964-4327
City Of Hope National Medical Center · USTranslational Genomics Research Institute · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Metabolic reprogramming is a hallmark of T-cell activation, and metabolic fitness is fundamental for T-cell-mediated antitumor immunity. Insights into the metabolic plasticity of chimeric antigen receptor (CAR) T cells in patients could help identify approaches to improve their efficacy in treating cancer. Here, we investigated the spatiotemporal immunometabolic adaptation of CD19-targeted CAR T cells using clinical samples from CAR T-cell-treated patients. Context-dependent immunometabolic adaptation of CAR T cells demonstrated the link between their metabolism, activation, differentiation, function, and local microenvironment. Specifically, compared with the peripheral blood, low lipid availability, high IL15, and low TGFβ in the central nervous system microenvironment promoted immunometabolic adaptation of CAR T cells, including upregulation of a lipolytic signature and memory properties. Pharmacologic inhibition of lipolysis in cerebrospinal fluid led to decreased CAR T-cell survival. Furthermore, manufacturing CAR T cells in cerebrospinal fluid enhanced their metabolic fitness and antileukemic activity. Overall, this study elucidates spatiotemporal immunometabolic rewiring of CAR T cells in patients and demonstrates that these adaptations can be exploited to maximize the therapeutic efficacy of CAR T cells. SIGNIFICANCE: The spatiotemporal immunometabolic landscape of CD19-targeted CAR T cells from patients reveals metabolic adaptations in specific microenvironments that can be exploited to maximize the therapeutic efficacy of CAR T cells.

Indexed as

Immunotherapy, AdoptiveNeoplasmsAntigens, CD19Central Nervous SystemHumansReceptors, Antigen, T-CellT-LymphocytesTumor MicroenvironmentAntigens, CD19Receptors, Antigen, T-Cell

Identifiers

PMID38315779
PMCPMC10984768
OpenAlexW4391528701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.